Similar articles

• Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.

  DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. DeWitt EM, et al. Arch Intern Med. 2006 Jan 9;166(1):57-63. doi: 10.1001/archinte.166.1.57. Arch Intern Med. 2006. PMID: 16401811
• Effective coverage and reimbursement strategies for etanercept and infliximab in the treatment of rheumatoid arthritis.

  Sokol MC. Sokol MC. Manag Care Interface. 2005 Apr;18(4):32-7. Manag Care Interface. 2005. PMID: 15889761
• [Anti-rheumatoid biologics and pharmacoeconomic evaluation].

  Tsutani K, Igarashi A. Tsutani K, et al. Nihon Rinsho. 2005 Jan;63 Suppl 1:711-8. Nihon Rinsho. 2005. PMID: 15799447 Review. Japanese. No abstract available.
• Anti-tumour necrosis factor therapy in the West Midlands.

  Bartram D, Sheeran T, Price T, Mulherin D. Bartram D, et al. Rheumatology (Oxford). 2004 Mar;43(3):400; author reply 400-1. doi: 10.1093/rheumatology/keh042. Rheumatology (Oxford). 2004. PMID: 14963219 No abstract available.
• The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.

  Jobanputra P, Barton P, Bryan S, Burls A. Jobanputra P, et al. Health Technol Assess. 2002;6(21):1-110. doi: 10.3310/hta6210. Health Technol Assess. 2002. PMID: 12387732 No abstract available.